Axovant Sciences Ltd  

(Public, NASDAQ:AXON)   Watch this stock  
Find more results for AXON
1.45
-0.17 (-10.49%)
After Hours: 1.45 0.00 (0.00%)
Feb 23, 4:37PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.43 - 1.63
52 week 1.43 - 27.98
Open 1.62
Vol / Avg. 2.78M/1.57M
Mkt cap 156.18M
P/E     -
Div/yield     -
EPS -2.36
Shares 107.79M
Beta     -
Inst. own 25%
May 23, 2018
Axon Kids AB Annual Shareholders Meeting (Estimated) - 3:00AM EDT - Add to calendar
Feb 12, 2018
Axovant Sciences Ltd. - Special Call - Webcast
Jan 9, 2018
Axovant Sciences Ltd at JPMorgan Healthcare Conference - Webcast
Jan 8, 2018
Axovant Sciences Ltd. - Special Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -104.97% -71.66%
Return on average equity -178.77% -92.42%
Employees 69 -
CDP Score - -

Address

20-22 Bedford Row
LONDON, WC1R 4JS
United Kingdom - Map
+44-1295-5950 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer's disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company is focused to develop its lead product candidate, intepirdine, a selective 5-hydroxytryptamine 6 receptor antagonist, for the treatment of Alzheimer’s disease and dementia with Lewy bodies (DLB). The Company also focuses on developing nelotanserin, a selective 5-hydroxytryptamine 2A receptor inverse agonist, for the treatment of rapid eye movement (REM) behavior disorder (RBD) in DLB patients, and visual hallucinations in patients with Lewy body dementia. The Company’s pipeline also includes RVT-103 and RVT-104.

Officers and directors

Vivek Ramaswamy Chairman of the Board
Age: 31
Bio & Compensation  - Reuters
Pavan Cheruvu Chief Executive Officer
Age: 36
Bio & Compensation  - Reuters
Gregory M. Weinhoff M.D. Chief Financial Officer
Age: 46
Bio & Compensation  - Reuters
Mark Altmeyer President of Axovant Sciences GmbH and Chief Commercial Officer
Age: 56
Bio & Compensation  - Reuters
Eric Floyd Ph.D. Senior Vice President - Regulatory Affairs
Bio & Compensation  - Reuters
Ilise Lombardo M.D. Senior Vice President - Clinical Research
Bio & Compensation  - Reuters
Thomas Templeman Ph.D. Senior Vice President - Pharmaceutical Operations and Quality Assurance
Bio & Compensation  - Reuters
Mark Wadley Senior Vice President, US Business
Bio & Compensation  - Reuters
Samina Bari Vice President - Corporate Communications
Bio & Compensation  - Reuters
Shankar Ramaswamy M.D. Vice President - Global Medical Affairs
Bio & Compensation  - Reuters